Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 4,540 Shares

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 4,540 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $48.76, for a total value of $221,370.40. Following the completion of the sale, the insider now directly owns 258,073 shares of the company’s stock, valued at $12,583,639.48. This represents a 1.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, December 4th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $46.07, for a total value of $307,056.55.
• On Wednesday, November 6th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $59.12, for a total transaction of $394,034.80.
• On Wednesday, October 2nd, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The shares were sold at an average price of $56.26, for a total transaction of $374,972.90.

Apogee Therapeutics Stock Performance

Shares of APGE stock traded up $0.18 on Friday, hitting $44.50. The stock had a trading volume of 691,879 shares, compared to its average volume of 504,108. The stock’s 50 day moving average is $51.43 and its 200-day moving average is $48.28. The firm has a market capitalization of $2.00 billion, a price-to-earnings ratio of -18.39 and a beta of 2.30. Apogee Therapeutics, Inc. has a 52-week low of $20.78 and a 52-week high of $72.29.

Institutional Trading of Apogee Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Apogee Therapeutics in the third quarter worth $71,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Apogee Therapeutics by 21.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock worth $94,000 after buying an additional 285 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of Apogee Therapeutics in the 2nd quarter valued at about $143,000. Wexford Capital LP bought a new stake in shares of Apogee Therapeutics during the 3rd quarter valued at about $230,000. Finally, Intech Investment Management LLC acquired a new stake in Apogee Therapeutics during the third quarter worth about $300,000. Institutional investors and hedge funds own 79.04% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $89.00 target price for the company. Guggenheim reaffirmed a “buy” rating on shares of Apogee Therapeutics in a research note on Thursday. Wedbush boosted their target price on Apogee Therapeutics from $87.00 to $90.00 and gave the stock an “outperform” rating in a research report on Monday, December 2nd. Finally, Canaccord Genuity Group began coverage on Apogee Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating and a $89.00 price target for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, Apogee Therapeutics has a consensus rating of “Buy” and an average target price of $83.88.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.